Proteinase-activated Receptor 2 Promotes Tumor Cell Proliferation and Metastasis by Inducing Epithelial-mesenchymal Transition and Predicts Poor Prognosis in Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2018 Mar 23

PMID 29563756

Citations 10

Authors

Liang Sun

Pi-Bao Li

Yan-Fen Yao

Ai-Yuan Xiu

Zhi Peng

Yu-Huan Bai

Yan-Jing Gao

Affiliations

Soon will be listed here.

Abstract

Aim: To clarify the role of proteinase-activated receptor 2 (PAR2) in hepatocellular carcinoma, especially in the process of metastasis.

Methods: PAR2 expression levels were assessed by qRT-PCR and immunohistochemistry (IHC) in patient tissues and in hepatocellular carcinoma cell lines SMMC-7721 and HepG2. Cell proliferation and metastasis were assessed both and . Immunoblotting was carried out to monitor the levels of mitogen-activated protein kinase (MAPK) and epithelial-mesenchymal transition markers.

Results: The prognosis was significantly poorer in patients with high PAR2 levels than in those with low PAR2 levels. Patients with high PAR2 levels had advanced tumor stage ( = 0.001, chi-square test), larger tumor size ( = 0.032, chi-square test), and high microvascular invasion rate ( = 0.037, chi-square test). The proliferation and metastasis ability of SMMC-7721 and HepG2 cells was increased after PAR2 overexpression, while knockdown of PAR2 decreased the proliferation and metastasis ability of SMMC-7721 and HepG2 cells. Knockdown of PAR2 also inhibited hepatocellular carcinoma tumor cell growth and liver metastasis in nude mice. Mechanistically, PAR2 increased the proliferation ability of SMMC-7721 and HepG2 cells ERK activation. Activated ERK further promoted the epithelial-mesenchymal transition of these cells, which endowed them with enhanced migration and invasion ability.

Conclusion: These data suggest that PAR2 plays an important role in the proliferation and metastasis of hepatocellular carcinoma. Therefore, targeting PAR2 may present a favorable target for treatment of this malignancy.

Citing Articles

Photonanozyme-Kras-ribosome combination treatment of non-small cell lung cancer after COVID-19.

Si Q, Bai M, Wang X, Wang T, Qin Y Front Immunol. 2024; 15:1420463.

PMID: 39308869 PMC: 11412844. DOI: 10.3389/fimmu.2024.1420463.

Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells.

Shah H, Hill T, Lim J, Fairlie D J Cell Commun Signal. 2023; 17(4):1293-1307.

PMID: 37991681 PMC: 10713943. DOI: 10.1007/s12079-023-00791-6.

Long non-coding RNA AC245100.4 activates the PI3K/AKT pathway to promote PCa cell proliferation by elevating PAR2.

Zhang K, Liu C, Hu C, Lin P, Qi Q, Jia H Heliyon. 2023; 9(6):e16870.

PMID: 37346322 PMC: 10279817. DOI: 10.1016/j.heliyon.2023.e16870.

Protease-Activated Receptor 2 (PAR2) Expressed in Sensory Neurons Contributes to Signs of Pain and Neuropathy in Paclitaxel Treated Mice.

Kume M, Ahmad A, DeFea K, Vagner J, Dussor G, Boitano S J Pain. 2023; 24(11):1980-1993.

PMID: 37315729 PMC: 10615692. DOI: 10.1016/j.jpain.2023.06.006.

PAR2: The Cornerstone of Pancreatic Diseases.

Suhaj P, Olejar T, Matej R Physiol Res. 2022; 71(5):583-596.

PMID: 36073735 PMC: 9841802. DOI: 10.33549/physiolres.934931.

References

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Grab D, Garcia-Garcia J, Nikolskaia O, Kim Y, Brown A, Pardo C . Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis. 2009; 3(7):e479. PMC: 2707606. DOI: 10.1371/journal.pntd.0000479. View

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T . Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology. 2017; 152(6):1395-1406.e10. DOI: 10.1053/j.gastro.2017.02.001. View

Kudo M . Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2005; 3(10 Suppl 2):S144-8. DOI: 10.1016/s1542-3565(05)00712-3. View

Cattaruzza F, Amadesi S, Carlsson J, Murphy J, Lyo V, Kirkwood K . Serine proteases and protease-activated receptor 2 mediate the proinflammatory and algesic actions of diverse stimulants. Br J Pharmacol. 2014; 171(16):3814-26. PMC: 4128045. DOI: 10.1111/bph.12738. View

Nystedt S, Emilsson K, Wahlestedt C, Sundelin J . Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A. 1994; 91(20):9208-12. PMC: 44781. DOI: 10.1073/pnas.91.20.9208. View

Kaufmann R, Mussbach F, Henklein P, Settmacher U . Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells. J Cancer Res Clin Oncol. 2010; 137(6):965-73. DOI: 10.1007/s00432-010-0961-1. View

Fortin J, Mak T . Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs. Cancer Cell. 2016; 29(4):429-431. DOI: 10.1016/j.ccell.2016.03.020. View

10.

Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T . ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 2006; 10(3):227-39. DOI: 10.1016/j.ccr.2006.07.020. View

11.

Kaufmann R, Oettel C, Horn A, Halbhuber K, Eitner A, Krieg R . Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 2009; 30(9):1487-96. DOI: 10.1093/carcin/bgp153. View

12.

Schneider A, Gautheron J, Feoktistova M, Roderburg C, Loosen S, Roy S . RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell. 2016; 31(1):94-109. DOI: 10.1016/j.ccell.2016.11.009. View

13.

Feng L, Dong H, Lau W, Yu H, Zhu Y, Zhao Y . Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2016; 143(2):293-303. DOI: 10.1007/s00432-016-2286-1. View

14.

Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L . Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008; 452(2):139-46. DOI: 10.1007/s00428-007-0558-5. View

15.

Schaffner F, Versteeg H, Schillert A, Yokota N, Petersen L, Mueller B . Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood. 2010; 116(26):6106-13. PMC: 3031395. DOI: 10.1182/blood-2010-06-289314. View

16.

Chua K, Poon K, Lim J, Sim W, Huang R, Thiery J . Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev. 2011; 63(8):558-67. DOI: 10.1016/j.addr.2011.02.003. View

17.

Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

18.

Nieto M, Huang R, Jackson R, Thiery J . EMT: 2016. Cell. 2016; 166(1):21-45. DOI: 10.1016/j.cell.2016.06.028. View

19.

Chan S, Wong V, Qin S, Chan H . Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2015; 34(1):83-90. DOI: 10.1200/JCO.2015.61.5724. View

20.

Kanemaru A, Yamamoto K, Kawaguchi M, Fukushima T, Lin C, Johnson M . Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2. Int J Cancer. 2016; 140(1):130-141. DOI: 10.1002/ijc.30426. View